ID   WM239A
AC   CVCL_6795
SY   WM-239A; WM-239-A; WM 239-A; WM 239A; WM-239; WM239; WM 239; WC00044
DR   BTO; BTO:0003474
DR   cancercelllines; CVCL_6795
DR   Cell_Model_Passport; SIDM00978
DR   Coriell; WC00044
DR   Cosmic; 888850
DR   Cosmic; 928690
DR   Cosmic; 972260
DR   Cosmic; 1155288
DR   Cosmic; 1155564
DR   Cosmic; 1303069
DR   Cosmic; 1477413
DR   GDSC; 1240225
DR   GEO; GSM109034
DR   GEO; GSM188232
DR   GEO; GSM188262
DR   GEO; GSM188321
DR   IARC_TP53; 24993
DR   PharmacoDB; WM239A_1670_2019
DR   Progenetix; CVCL_6795
DR   Rockland; WM239A-01-0001
DR   Wikidata; Q54994215
RX   PubMed=2253310;
RX   PubMed=3020539;
RX   PubMed=3856042;
RX   PubMed=4053039;
RX   PubMed=15009714;
RX   PubMed=16827748;
RX   PubMed=18632627;
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (PubMed=15009714; Wistar).
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: Coriell; WC00044; probable.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): Wistar
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D21S11: 28,29
ST   D5S818: 12,13
ST   D7S820: 7,8
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0040 ! WM115
OI   CVCL_L033 ! WM165-1
OI   CVCL_RN55 ! WM165-2
OI   CVCL_RN56 ! WM239B
OI   CVCL_RN57 ! WM266-1
OI   CVCL_RN58 ! WM266-2
OI   CVCL_RN59 ! WM266-3
OI   CVCL_2765 ! WM266-4
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
RX   PubMed=3020539; DOI=10.1073/pnas.83.19.7197;
RA   Westermark B., Johnsson A., Paulsson Y., Betsholtz C., Heldin C.-H.,
RA   Herlyn M., Rodeck U., Koprowski H.;
RT   "Human melanoma cell lines of primary and metastatic origin express
RT   the genes encoding the chains of platelet-derived growth factor (PDGF)
RT   and produce a PDGF-like growth factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:7197-7200(1986).
RX   PubMed=3856042; DOI=10.1093/jnci/74.2.283;
RA   Herlyn M., Balaban G.B., Bennicelli J.L., Guerry D. IV, Halaban R.,
RA   Herlyn D., Elder D.E., Maul G.G., Steplewski Z., Nowell P.C.,
RA   Clark W.H. Jr., Koprowski H.;
RT   "Primary melanoma cells of the vertical growth phase: similarities to
RT   metastatic cells.";
RL   J. Natl. Cancer Inst. 74:283-289(1985).
RX   PubMed=4053039;
RA   Herlyn M., Thurin J., Balaban G.B., Bennicelli J.L., Herlyn D.,
RA   Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H. Jr.,
RA   Koprowski H.;
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).